Arteriovenous Graft ThrombosisNCT07613632
Changes in Regional Ventilation-Perfusion Match Following Percutaneous Transluminal Angioplasty for Arteriovenous Graft Thrombosis
An observational study of Arteriovenous Graft Thrombosis and End Stage Renal Disease on Dialysis, run by First Affiliated Hospital of Wannan Medical College at 1 site in China.
Trial summary
Patients with end-stage renal disease (ESRD) often require arteriovenous grafts (AVG) for hemodialysis. AVG thrombosis is a common complication, usually managed by percutaneous transluminal angioplasty (PTA) to restore blood flow. PTA achieves patency by balloon-mediated compression and fragmentation of thrombus. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Arteriovenous Graft Thrombosis, End Stage Renal Disease on Dialysis
- What is being tested?
- Electrical Impedance Tomography (EIT) Monitoring
- How many people
- 20 participants
- Where
- 1 siteChina
- Study dates
- 24 Oct 2024to 30 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with end-stage renal disease (ESRD) undergoing maintenance hemodialysis who present with thrombosed arteriovenous grafts (AVG) requiring clinically indicated percutaneous transluminal angioplasty (PTA) to restore patency. The study population will consist of adult patients (18-80 years) admitted to the interventional radiology or dialysis access unit of the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital). All participants will receive routine PTA treatment as part of standard care. EIT monitoring will be applied non-invasively to collect ventilation and perfusion signals before and after PTA. No additional interventions beyond routine clinical management will be introduced.
Who may be able to join
- Age ≥ 18 years.
- Diagnosis of end-stage renal disease receiving maintenance hemodialysis.
- Documented AVG thrombosis requiring PTA.
- Able to cooperate and tolerate EIT monitoring.
- Provided written informed consent.
Who cannot join
- Severe respiratory failure incompatible with supine position.
- Thoracic skin condition or deformity preventing EIT electrode placement.
- Acute pulmonary embolism or acute pulmonary edema before procedure.
- NYHA Class IV heart failure or hemodynamic instability.
- Pregnancy or breastfeeding.
- Any other circumstance judged unsuitable by investigator.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College)
Wuhu
Shengsheng xu, 86-18315329399, taoshengsheng@yjsyy.com
About this study
Official title: Changes in Regional Ventilation-Perfusion Match Following Percutaneous Transluminal Angioplasty for Arteriovenous Graft Thrombosis: A Prospective Observation Pilot Study
Patients with end-stage renal disease (ESRD) often require arteriovenous grafts (AVG) for hemodialysis. AVG thrombosis is a common complication, usually managed by percutaneous transluminal angioplasty (PTA) to restore blood flow. PTA achieves patency by balloon-mediated compression and fragmentation of thrombus. Small thrombus fragments may enter the venous circulation and cause transient pulmonary microembolism, leading to ventilation-perfusion (V/Q) mismatch. This study uses electrical impedance tomography (EIT) to noninvasively monitor short-term changes in regional ventilation and perfusion during and after PTA, exploring the immediate pulmonary physiological consequences of thrombus fragmentation and revascularization in dialysis patients.
Read the detailed description
Arteriovenous graft (AVG) thrombosis is a major source of vascular access failure in ESRD. PTA restores patency through balloon dilation and mechanical thrombus compression. Minor embolic debris can reach the pulmonary bed, transiently disturbing perfusion distribution and V/Q matching. Because the pulmonary circulation is sensitive to sudden peripheral hemodynamic shifts, the PTA period provides a unique opportunity to observe lung perfusion response dynamically.
This single-center, prospective, observational pilot study will continuously record regional ventilation and perfusion by EIT at six time points: 10 min before PTA, at recanalization, and 10, 20, 30 min after, and at procedure completion. Measured variables include: V/Q matching index (primary), physiological dead space fraction (Vd/Vt), intrapulmonary shunt fraction, SPO₂/FiO₂ ratio, and hemodynamic data (balloon pressure, recanalization time, blood flow recovery). Results will be analyzed using repeated-measures ANOVA or mixed-effects modeling.
- Being tested
- Electrical Impedance Tomography (EIT) Monitoring
- Keywords
- Percutaneous Transluminal Angioplasty, Electrical Impedance Tomography, Ventilation-Perfusion Matching, Pulmonary Microembolism, Dead Space, Shunt, Pilot Study
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Electrical Impedance Tomography (EIT) MonitoringDiagnostic test
Non-invasive 16-electrode EIT belt applied at the 4th intercostal level. Continuous data acquisition begins 10 min pre-PTA, continues throughout balloon angioplasty, and up to 30 min post-recanalization. No alteration to standard clinical care.
| Study group | Role | What they receive |
|---|---|---|
| Observation Cohort | All enrolled patients will undergo clinically indicated PTA under standard care. EIT monitoring will be performed continuously before, during, and after recanalization to record regional ventilation and perfusion data. No experimental drug or device will be administered beyond routine care. Receives: Diagnostic Test: Electrical Impedance Tomography (EIT) Monitoring |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Ventilation-Perfusion Matching Index
Quantitative index derived from EIT ventilation and perfusion maps, indicating spatial regional correlation of air and blood flow distribution.
Measured: Baseline (10 min before PTA), immediate post-recanalization, 10, 20, 30 minutes, and procedure end.
Secondary outcomes (4)
Change in Peripheral Oxygen Saturation
Measured: Baseline (10 min before PTA), immediate post-recanalization, 10, 20, 30 minutes, and procedure end.
Change in Physiological Dead Space Fraction
Ratio of physiologic dead space to tidal volume, calculated by EIT validated algorithm, reflecting inefficiency of ventilation.
Measured: Baseline (10 min before PTA), immediate post-recanalization, 10, 20, 30 minutes, and procedure end.
Change in Intrapulmonary Shunt Fraction
Percentage of the lung region showing perfusion without ventilation, estimated from EIT perfusion signals.
Measured: Baseline (10 min before PTA), immediate post-recanalization, 10, 20, 30 minutes, and procedure end.
Change in Regional Ventilation and Perfusion Distribution
Variation in spatial patterns of pulmonary ventilation and perfusion derived from pixel-based EIT data.
Measured: Baseline (10 min before PTA), immediate post-recanalization, 10, 20, 30 minutes, and procedure end.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2026
- Study start24 Oct 2024
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Arteriovenous Graft ThrombosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- First Affiliated Hospital of Wannan Medical College
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Qiancheng Xu, First Affiliated Hospital of Wannan Medical College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07613632
- Sponsor's protocol ID
- 2026-ICU04
- Status last verified
- May 2026
- First submitted
- 23 May 2026
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Changes in Regional Ventilation-Perfusion Match Following Percutaneous Transluminal Angioplasty for Arteriovenous Graft Thrombosis: A Prospective Observation Pilot Study
- ClinicalTrials.gov ID
- NCT07613632
- Acronym / sponsor ID
- 2026-ICU04
- Keywords
- Percutaneous Transluminal Angioplasty, Electrical Impedance Tomography, Ventilation-Perfusion Matching, Pulmonary Microembolism, Dead Space, Shunt, Pilot Study
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- First Affiliated Hospital of Wannan Medical CollegeUniversity, hospital or other
- Study start
- 24 Oct 2024 (actual)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Dec 2027 (estimated)
- First posted
- 29 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with end-stage renal disease (ESRD) often require arteriovenous grafts (AVG) for hemodialysis. AVG thrombosis is a common complication, usually managed by percutaneous transluminal angioplasty (PTA) to restore blood flow. PTA achieves patency by balloon-mediated compression and fragmentation of thrombus. Small thrombus fragments may enter the venous circulation and cause transient pulmonary microembolism, leading to ventilation-perfusion (V/Q) mismatch. This study uses electrical impedance tomography (EIT) to noninvasively monitor short-term changes in regional ventilation and perfusion during and after PTA, exploring the immediate pulmonary physiological consequences of thrombus fragmentation and revascularization in dialysis patients.
Detailed description
Arteriovenous graft (AVG) thrombosis is a major source of vascular access failure in ESRD. PTA restores patency through balloon dilation and mechanical thrombus compression. Minor embolic debris can reach the pulmonary bed, transiently disturbing perfusion distribution and V/Q matching. Because the pulmonary circulation is sensitive to sudden peripheral hemodynamic shifts, the PTA period provides a unique opportunity to observe lung perfusion response dynamically.
This single-center, prospective, observational pilot study will continuously record regional ventilation and perfusion by EIT at six time points: 10 min before PTA, at recanalization, and 10, 20, 30 min after, and at procedure completion. Measured variables include: V/Q matching index (primary), physiological dead space fraction (Vd/Vt), intrapulmonary shunt fraction, SPO₂/FiO₂ ratio, and hemodynamic data (balloon pressure, recanalization time, blood flow recovery). Results will be analyzed using repeated-measures ANOVA or mixed-effects modeling.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observation Cohort | – | Diagnostic Test: Electrical Impedance Tomography (EIT) MonitoringAll enrolled patients will undergo clinically indicated PTA under standard care. EIT monitoring will be performed continuously before, during, and after recanalization to record regional ventilation and perfusion data. No experimental drug or device will be administered beyond routine care. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with end-stage renal disease (ESRD) undergoing maintenance hemodialysis who present with thrombosed arteriovenous grafts (AVG) requiring clinically indicated percutaneous transluminal angioplasty (PTA) to restore patency. The study population will consist of adult patients (18-80 years) admitted to the interventional radiology or dialysis access unit of the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital). All participants will receive routine PTA treatment as part of standard care. EIT monitoring will be applied non-invasively to collect ventilation and perfusion signals before and after PTA. No additional interventions beyond routine clinical management will be introduced.
Key inclusion criteria (5 listed)
- Age ≥ 18 years.
- Diagnosis of end-stage renal disease receiving maintenance hemodialysis.
- Documented AVG thrombosis requiring PTA.
- Able to cooperate and tolerate EIT monitoring.
- Provided written informed consent.
Key exclusion criteria (6 listed)
- Severe respiratory failure incompatible with supine position.
- Thoracic skin condition or deformity preventing EIT electrode placement.
- Acute pulmonary embolism or acute pulmonary edema before procedure.
- NYHA Class IV heart failure or hemodynamic instability.
- Pregnancy or breastfeeding.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Electrical Impedance Tomography (EIT) MonitoringNon-invasive 16-electrode EIT belt applied at the 4th intercostal level. Continuous data acquisition begins 10 min pre-PTA, continues throughout balloon angioplasty, and up to 30 min post-recanalization. No alteration to standard clinical care. | Diagnostic test | Observation Cohort |
Primary outcome
Change in Ventilation-Perfusion Matching Index
Time frame: Baseline (10 min before PTA), immediate post-recanalization, 10, 20, 30 minutes, and procedure end.
Quantitative index derived from EIT ventilation and perfusion maps, indicating spatial regional correlation of air and blood flow distribution.
4 secondary outcomes
Change in Peripheral Oxygen Saturation
Time frame: Baseline (10 min before PTA), immediate post-recanalization, 10, 20, 30 minutes, and procedure end.
Change in Physiological Dead Space Fraction
Time frame: Baseline (10 min before PTA), immediate post-recanalization, 10, 20, 30 minutes, and procedure end.
Change in Intrapulmonary Shunt Fraction
Time frame: Baseline (10 min before PTA), immediate post-recanalization, 10, 20, 30 minutes, and procedure end.
Change in Regional Ventilation and Perfusion Distribution
Time frame: Baseline (10 min before PTA), immediate post-recanalization, 10, 20, 30 minutes, and procedure end.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Arteriovenous Graft Thrombosis and End Stage Renal Disease on Dialysis, run by First Affiliated Hospital of Wannan Medical College at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact qiancheng xu, PhD (+86-18297529106, qianchengxu@wnmc.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Ventilation-Perfusion Matching Index (time frame: Baseline (10 min before PTA), immediate post-recanalization, 10, 20, 30 minutes, and procedure end.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.